Chief Financial Officer, Principal Financial Officer · ROCKET PHARMACEUTICALS, INC. (RCKT)

Aaron Ondrey

FY2024 is the first fiscal year CompBrief holds for Aaron Ondrey as a named executive officer of ROCKET PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,989,763

Salary $362,662Stock awards $1,249,988

3rd of 6 named executive officers at Rocket Pharmaceuticals by FY2024 total.

6 named officers on file for ROCKET PHARMACEUTICALS, FY2024

Aaron Ondrey’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • RCKT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ROCKET PHARMACEUTICALS’s whole pay program stands against its peers

  • ROCKET PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RCKT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Aaron Ondrey’s full pay file as a PDF — free

More than this page: up to 10 years of Aaron’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Aaron Ondrey compensation by year

ROCKET PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as ROCKET PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$362,662
Bonus$0
Stock awards$1,249,988
Option awards$1,249,983
Non-equity incentive$117,502
Pension and deferred compensation$0
All other$9,628
Total$2,989,763

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ROCKET PHARMACEUTICALS, INC. DEF 14A filed April 30, 2025, accession 0001140361-25-016656, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ROCKET PHARMACEUTICALS, INC. filed document, accession 0001140361-25-016656. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU46,781$588,637—
Option69,337—$26.72

Per the Outstanding Equity Awards at Fiscal Year-End table in ROCKET PHARMACEUTICALS, INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2024 proxy (filed April 30, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-07-03Sale—1,477$2.88128,173

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ROCKET PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Gaurav ShahChief Executive Officer$6,841,407
Kinnari PatelPresident, Head of R&D and Chief Operating Officer$6,696,055
Aaron Ondrey · this pageChief Financial Officer, Principal Financial Officer$2,989,763
Jonathan SchwartzChief Medical and Gene Therapy Officer$2,364,309
Martin WilsonGeneral Counsel and Chief Corporate Officer, Senior VP$2,113,954
John MilitelloPrincipal Accounting Officer and Former Interim Principal Financial Officer, Vice President$1,175,588

The full ROCKET PHARMACEUTICALS compensation record

free company brief

This page is one person within ROCKET PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ROCKET PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ROCKET PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Aaron Ondrey's compensation dossier · One-time report. No refunds.